Table 1.
Demographic characteristics of participants (N = 1002).
| Characteristics | Same Brand and Type of Vaccine (n = 791) |
Different Brand but Same Type of Vaccine (n = 164) |
Different Brand and Different Type of Vaccine (n = 47) |
|---|---|---|---|
| Age (years), mean (SD) | 30.7 (10.6) | 32.0 (10.4) | 45.4 (11.2) |
| Age range (years) | 18–77 | 18–68 | 18–65 |
| Gender | |||
| Female | 393 (49.7%) | 75 (45.7%) | 22 (46.8%) |
| Male | 382 (48.3%) | 89 (54.3%) | 25 (53.2%) |
| Other (e.g., non-binary, genderqueer) | 16 (2.0%) | 0 (0.0%) | 0 (0.0%) |
| Race | |||
| White or Caucasian | 451 (57.0%) | 110 (67.1%) | 39 (83.0%) |
| East Asian | 116 (14.7%) | 19 (11.6%) | 2 (4.3%) |
| South Asian or Indian | 55 (7.0%) | 11 (6.7%) | 5 (10.6%) |
| Southeast Asian | 55 (7.0%) | 11 (6.7%) | 0 (0.0%) |
| Black or African American | 39 (4.9%) | 2 (1.2%) | 1 (2.1%) |
| Hispanic or Latino | 26 (3.3%) | 4 (2.4%) | 0 (0.0%) |
| Mixed or Multi-racial | 22 (2.8%) | 4 (2.4%) | 0 (0.0%) |
| West Asian or Middle Eastern | 21 (2.7%) | 2 (1.2%) | 0 (0.0%) |
| Native Canadian or Indigenous | 5 (0.6%) | 1 (0.6%) | 0 (0.0%) |
| Native Hawaiian or other Pacific Islander | 1 (0.1%) | 0 (0.0%) | 0 (0.0%) |
| Marital Status | |||
| Single | 505 (63.8%) | 96 (58.5%) | 9 (19.1%) |
| Married | 268 (33.9%) | 62 (37.8%) | 36 (76.6%) |
| Divorced, separated, widowed | 18 (2.3%) | 6 (3.7%) | 2 (4.3%) |
| Have children | |||
| Yes | 202 (25.5%) | 43 (26.2%) | 24 (51.1%) |
| No | 589 (74.5%) | 121 (73.8%) | 23 (48.9%) |
| Practice some type of religion | |||
| Yes | 307 (38.8%) | 64 (39.0%) | 26 (55.3%) |
| No | 484 (61.2%) | 100 (61.0%) | 21 (44.7%) |
| Household income | |||
| $0 to $29,999 CAD | 101 (12.8%) | 22 (13.4%) | 5 (10.6%) |
| $30,000 to $49,999 CAD | 93 (11.8%) | 21 (12.8%) | 3 (6.4%) |
| $50,000 to $74,999 CAD | 184 (23.3%) | 44 (26.8%) | 6 (12.8%) |
| $75,000 to $99,999 CAD | 133 (16.8%) | 32 (19.5%) | 7 (14.9%) |
| $100,000 to $149,999 CAD | 174 (22.0%) | 30 (18.3%) | 16 (34.0%) |
| $150,000 to $199,999 CAD | 58 (7.3%) | 9 (5.5%) | 5 (10.6%) |
| $200,000 CAD and over | 48 (6.1%) | 6 (3.7%) | 5 (10.6%) |
| Annual influenza vaccine frequency | |||
| Every year | 187 (23.6%) | 40 (24.4%) | 15 (31.9%) |
| Almost every year | 155 (19.6%) | 40 (24.4%) | 15 (31.9%) |
| Sometimes (every few years) | 234 (29.6%) | 35 (21.3%) | 11 (23.4%) |
| Never | 215 (27.2%) | 49 (29.9%) | 6 (12.8%) |
| Ever been infected with COVID-19 | |||
| Yes | 35 (4.4%) | 7 (4.3%) | 2 (4.3%) |
| No | 756 (95.6%) | 157 (95.7%) | 45 (95.7%) |
| 1st COVID-19 vaccine type | |||
| Pfizer-BioNTech (BNT162b2) | 587 (74.2%) | 136 (82.9%) | 1 (2.1%) |
| Moderna (mRNA-1273) | 188 (23.8%) | 27 (16.5%) | 3 (6.4%) |
| Oxford-AstraZeneca (ChAdOx1) | 16 (2.0%) | 1 (0.6%) | 43 (91.5%) |
| Janssen (Johnson & Johnson) (Ad26.COV2.S) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| 2nd COVID-19 vaccine type | |||
| Pfizer-BioNTech (BNT162b2) | 587 (74.2%) | 27 (16.5%) | 19 (40.4%) |
| Moderna (mRNA-1273) | 188 (23.8%) | 136 (82.9%) | 24 (51.1%) |
| Oxford-AstraZeneca (ChAdOx1) | 16 (2.0%) | 0 (0.0%) | 3 (6.4%) |
| Janssen (Johnson & Johnson) (Ad26.COV2.S) | 0 (0.0%) | 1 (0.6%) | 1 (2.1%) |